This topic contains 0 replies, has 1 voice, and was last updated by  Pulmonary Fibrosis News Moderator 1 month, 2 weeks ago.

  • Author
    Posts
  • #20598

    Director of Multichannel Content for Pulmonary Fibrosis News, Michael Morale, discusses how a study is showing that the investigational therapy PRM-151 is slowing disability progression up to 76 weeks in IPF patients.

    What are your thoughts on this news?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account